cent in different States, communities like Sindhis, Punjabis, Lohanas, Kutchi Bhanushalis, Jains and Bohris have a higher prevalence (4-17%) [7] [8] [9] [10] [11] [12] . Different reports have estimated that 7500-12,000 β-thalassaemia major babies would be born in India each year 12 -14 . It has also been shown recently by micromapping at the district level in two States, Maharashtra and Gujarat in western India that the prevalence of β-thalassaemia trait in different districts within these States is variable (0 -9.5%). Based on these estimates there would be around 1000 births of β-thalassaemia major babies each year in these two States alone 15 . Thus, such data should be obtained from different States to know the true burden of the disease and for planning and executing control programmes.
Haemoglobin S (Hb S) is prevalent in central India and among the tribal belts in western, eastern and southern India, the carrier rates varying from 1-40 per cent [16] [17] [18] . It has been estimated that over 5000 babies with sickle cell disease would be born each year 19 .
Haemoglobin E is widespread in the north eastern States in Assam, Mizoram, Manipur, Arunachal Pradesh and Tripura, the prevalence of Hb E trait being highest (64%) among the Bodo-Kacharis in Assam and going up to 30-40 per cent in some other populations in this region [20] [21] [22] . In eastern India the prevalence of Hb E trait varies from 3-10 per cent in West Bengal 8, 23 . Both Hb E and Hb S when co-inherited with β-thalassaemia result in a disorder of variable clinical severity [24] [25] [26] .
These inherited haemoglobin disorders cause considerable pain and suffering to the patients and their families and are a major drain on health resources in the country.
The need for accurate identification of carries and couples at risk
Classical β-thalassaemia carriers have typically reduced red cell indices [mean corpuscular volume (MCV)<80 fl, mean corpuscular haemoglobin (MCH)<27 pg] with high RBC counts and elevated HbA 2 levels (4-8%) 27 . However, a few β-thalassaemia heterozygotes fail to manifest these classical haematological features and are termed as silent carriers or normal HbA 2 β-thalassaemia carriers. Individuals with borderline HbA 2 levels (3.3 to 3.9%) need to be evaluated carefully to avoid a misdiagnosis. Mutations in the promoter region of the β-globin gene like -86 (CG), -87 (CG), -88 (CT), -101 (CT) as well as the capsite +1 (AC) and the poly A (TC) mutation can lead to borderline Hb A 2 levels 28 . Among these, the capsite +1 (AC) mutation is seen in 1-2.5 per cent of β-thalassaemia heterozygotes in India [29] [30] [31] . Other factors like associated α-thalassaemia or δ-thalassaemia and iron deficiency anaemia may also contribute in reduction of HbA 2 levels 28, 32, 33 .
It is also important to identify carriers of δβ-thalassaemia as compound heterozygotes of δβ-thalassaemia and β-thalassaemia can lead to a severe disorder. δβ-thalassaemia carriers are characterized by a modest elevation in Hb F levels (5-20%) with reduced or normal HbA 2 levels and hypochromic and microcytic red cells. This phenotype partially overlaps with that of carriers of hereditary persistence of foetal haemoglobin (HPFH) and genotyping of high Hb F determinants is required as these are not infrequent in India. The common determinant of δβ-thalassaemia in India is the Asian Indian deletional inversion Gγ(Aγδβ) o thalassaemia 34 .
The most appropriate time to screen
Screening in antenatal clinics is the best way to identify couples at immediate risk of having an affected child. However, experiences in India have shown that only 15-20 per cent of pregnant women come to antenatal clinics in public hospitals in the first trimester of pregnancy when prenatal diagnosis should ideally be done 11, 35 . This emphasizes the need for generating awareness in the population for early registration in antenatal clinics as well as among obstetricians to ask for a screening for β-thalassaemia and other haemoglobinopathies along with other investigations which are done routinely. The other target groups for screening in India include high school children, college or university students, high risk communities and extended family members of affected children 11, 12, 36 . The latter cascade screening approach appears to be a practical way of identifying a larger number of β-thalassaemia carriers in a cost-effective way in India. The large size of families as well as the system of living in joint families rather than nuclear ones is an advantage in this approach.
Genetic counselling
Genetic counselling plays a major role in a prevention programme. The Indian population comprises several ethnic groups with considerable cultural and religious diversity and this has to be kept in mind while counselling families to avoid social stigmatization 37 . The influence of elders in the family also weighs heavily and has to be dealt with appropriately. While earlier, parents with a thalassaemia major child kept to themselves, today their relatives and extended families are coming forward to get screened 38 . There is only one centre in Lucknow in north India which offers a formal course for genetic counsellors and there is a need for more such courses throughout the country.
Counsellors should be aware that couples at risk of having a child with β-thalassaemia major, sickle cell disease, Hb S β-thalassaemia, Hb E β-thalassaemia, δβ -β-thalassaemia, Hb Lepore β-thalassaemia and Hb SD disease should be given the option of prenatal diagnosis to avoid the birth of a child with a severe disorder. However, couples at risk of having a child with Hb D disease, Hb D β-thalassaemia and Hb E disease do not require prenatal diagnosis as these disorders are mild.
In Sardinia, identification of the maximum number of carriers followed by effective genetic counselling helped to reduce the birth rate of β-thalassaemia major babies from 1:250 to 1:4000 39 .
Prenatal diagnosis The first initiatives in India
Facilities for prenatal diagnosis became available in India in the mid 1980s 40 . Until then, although prenatal diagnosis was offered by a few centres, foetal samples were sent to the UK and other countries for analysis. Foetal blood sampling by foetoscopy done between 18 and 22 wk gestation and diagnosis by globin chain synthesis were done for the next 4 to 5 years at 2 centres in Mumbai 40, 41 .
Chorionic villus sampling and DNA analysis in the first trimester
In the 1990s first trimester foetal diagnosis by chorionic villus sampling (CVS) and DNA analysis was established at 4-5 centres in the north in Delhi 42 , in the west in Mumbai 41, 43, 44 and in the south in Vellore 45 . These services then expanded to other cities like Lucknow and Chandigarh in the north 46, 47 , and Kolkata in the east 48 . However, these services are still limited to major cities where couples are referred to or CVS samples are sent from surrounding areas.
Molecular analysis
β-thalassaemia is extremely heterogeneous with more than 200 mutations described worldwide 49 . In India, about 64 mutations have been characterized by studies done at different centres 30, 31, [49] [50] [51] (Table I) However, regional differences in their frequencies have been noted 30, 31, 50, 51 (Fig. 1) . The prevalence of IVS 1 -5 (GC), the most common mutation in India varies from 15-88 per cent in different States. Codon 15 (GA) is the second most frequent mutation in Maharashtra and Karnataka and Codon 5 (-CT) is the third most common mutation in Gujarat. The -88 (CT) and the Cap site +1 (AC) mutations are more common in the northern region 30, 31, 50 . The 619 bp deletion is the most common mutation among the immigrant population from Pakistan.
This knowledge on the distribution of mutations in different regions and in people of different ethnic backgrounds has facilitated prenatal diagnosis using molecular techniques like covalent reverse dot blot hybridization (CRDB), amplification refractory mutation system (ARMS), denaturing gradient gel electrophoresis (DGGE), and DNA sequencing 43, 44, 52 .
Foetal blood analysis in the second trimester
Most of the prenatal diagnosis programmes in the Mediterranean countries started with second trimester foetal blood analysis but they were able to switch over to first trimester diagnosis in a short span 5, 39 .
In India, second trimester diagnosis is still done as many couples at risk are identified late during pregnancy. Foetal blood sampling is done by cordocentesis at 18 to 20 wk gestation and after confirming that there is no maternal contamination in the foetal sample by foetal cell staining using the Kleihauer-Betke method, it is analysed by HPLC on the Variant Hemoglobin Testing System (Bio Rad Laboratories, Hercules, USA). The Hb A levels in foetuses affected with β-thalassaemia major have ranged from 0 to 0.5 per cent and these were distinguishable from heterozygous babies where the Hb A levels were >1.3 per cent in different studies. However, there was some overlap in Hb A levels between heterozygotes and normals [53] [54] [55] . Sickle cell disease and Hb E thalassaemia have also been diagnosed in this way. On the other hand, experience in Thailand showed that while β 0 thalassaemia homozygotes and Hb E -β 0 thalassaemia compound heterozygotes could be diagnosed by HPLC analysis of foetal blood, β ++ thalassaemia homozygotes may be misdiagnosed as heterozygotes 56 .
Amniotic fluid cells have not been used extensively in India for prenatal diagnosis of haemoglobinopathies. Both first and second trimester prenatal diagnosis for the β-thalassaemias and sickle cell disorders are done at National Institute of Immunohaematology, Mumbai, and over the last 25 years 2,221 pregnancies at risk have been investigated (Table II) . While majority of the couples were at risk of having children with β-thalassaemia major, a significant number of couples at risk of having children with sickle cell disorders have been referred for prenatal diagnosis in the last 4 to 5 years. Our experience in western India has shown that there are still very few couples (<10%) who come prospectively in the first pregnancy for prenatal diagnosis of the β-thalassaemias while 25 -35 per cent of couples come prospectively for prenatal diagnosis of sickle cell disorders. This is a reflection of the greater awareness in regions particularly in Maharashtra and Gujarat where sickle cell disorders are common. Realizing the need for more centres for prenatal diagnosis in the country, the Indian Council of Medical Research, New Delhi, is trying to establish regional centres with the help of NIIH, Mumbai, in Nagpur in Maharashtra, Valsad and Surat in Gujarat, Bangalore in Karnataka, Kolkata in West Bengal and Ludhiana in Punjab mainly in medical colleges.
Non-invasive prenatal diagnosis from maternal blood
Current methods for obtaining foetal genetic material like chorionic villus sampling, amniocentesis and cordocentesis are invasive procedures which are associated with a small risk of foetal loss even when done by experienced hands 57 . This has led to many studies on the possibility of accessing foetal cells from the maternal circulation for non-invasive diagnosis.
Isolation of foetal cells from maternal blood
Trophoblasts, lymphocytes and nucleated erythrocytes (NRBCs) were the 3 cell types used as a source of foetal DNA. Foetal NRBCs were most widely used as they are mononuclear, are specific to the ongoing pregnancy and can be detected in the first trimester. These express several antigens like transferrin receptor and produce foetal haemoglobin chains like zeta (ζ), epsilon (ε) and gamma (γ) which are useful markers 58, 59 . However, their numbers in the maternal circulation during pregnancy are only a few. It is estimated that around 2 µl of foetal blood crosses into the maternal circulation per day in the first and second trimesters and 1/50,000 cells are of foetal origin. Thus enrichment of foetal NRBCs was done by density gradient centrifugation using percoll or ficoll and isolation of the cells by fluorescence activated cell sorting (FACS) or magnetic activated cell sorting (MACS) using different monoclonal antibodies or pick up of single NRBCs after staining by microdissection 60 .
A few reports were published on the noninvasive prenatal diagnosis of sickle cell anaemia and β-thalassaemia using foetal NRBCs and PCR based protocols [61] [62] [63] . The number of pregnancies studied were few and accurate diagnosis was not possible in every case.
Our experience
We attempted non-invasive prenatal diagnosis of β-thalassaemia major, sickle cell disorders and Hb E β-thalassaemia by isolating foetal NRBCs from 7 ml of maternal blood at different periods of gestation in 100 cases. As shown schematically in Fig. 2 , after percoll density gradient centrifugation for enrichment of foetal NRBCs, a combination of 3 monoclonal antibodies CD 45, Glycophorin A(GpA) and anti-Hb F were used for flow sorting. The CD45 negative cells were first selected and from this population the cells which were dual positive for Gycophorin A and Hb F were sorted. Foetal NRBCs could be isolated between 9 and 22 wk gestation although maximum number of cells were obtained between 10 and 14 wk gestation. DNA was isolated from the sorted foetal NRBCs and a nested ARMS PCR approach was developed for the detection of 12 different mutations. The foetal genotype was correctly determined in 84 of the 100 cases (84%). In 10 cases, the diagnosis was incorrect due to maternal contamination in the flow sorted cells and in 6 cases this was due to non amplification of alleles 64 . In another 30 pregnancies substituting Glycophorin A by CD 71 increased the accuracy of diagnosis to 90 per cent. Thus, the problems of maternal contamination and allele dropouts remain.
Circulatory foetal DNA in maternal plasma
The discovery of cell free foetal DNA in maternal plasma by Lo et al 65 opened up new avenues for noninvasive prenatal diagnosis. However, for the diagnosis of monogenic disorders like the thalassaemias, this approach is still a challenge as foetal DNA represents only 5 per cent of the DNA in maternal plasma 66 , although recently it has been shown to be present in higher concentrations (10-20%) 67 . It was shown that foetal DNA fragments are smaller in size (<313 bp) than maternal DNA fragments (>1 kb) and cell free foetal DNA in maternal plasma can be enriched by size fractionation on agarose gels 68 . Most of the reports so far have been based on detection or exclusion of paternal β-thalassaemia mutations when the maternal and paternal mutations are different or on the efficacy of detection of informative single nucleotide polymorphisms (SNPs) linked to the paternal mutant or normal allele. The diagnostic methods used have included real time allele specific PCR, allele specific arrayed primer extension (AS-APEX) technology, conventional PCR -DGGE and MALDI-TOF mass spectrometry [69] [70] [71] [72] [73] [74] [75] [76] .
The potential disadvantage of most of these studies is that only paternally inherited alleles can be studied and invasive procedures may still be required in many cases when the paternal mutation is present. Besides, the technology is sophisticated and would not be available at many diagnostic laboratories.
Our experience with cell free foetal DNA analysis Fig. 3 shows the approach used by us for prenatal diagnosis using cell free foetal DNA from maternal plama. In 30 couples where the paternal and maternal mutations were different, we extracted DNA from maternal plasma. After size separation on agarose gels a fragment of about 300 bp was excised and used for looking for the presence or absence of the paternal mutation by semi-nested PCR. An accuracy of 80 per cent was achieved (unpublished data).
The future
It has been predicted that within the next 10 years, the complete foetal genome from maternal plasma would be successfully sequenced. The main technology for non-invasive prenatal diagnosis even for monogenic disorders could be based on single molecule analysis methods. Digital PCR and massively parallel sequencing would be the technology used 77 . Fig. 2 . Schematic representation of the approach used for noninvasive prenatal diagnosis using foetal nucleated red blood cells (NRBCs) from maternal blood. Fig. 3 . Schematic representation of the approach used for noninvasive prenatal diagnosis using circulating cell free foetal DNA from maternal plasma.
